We are committed to being a socially responsible and sustainable company
by listening to our stakeholders’ voices and understanding what their expectations are.
Samsung Bioepis is committed to pursuing sustainability management with a focus on ESG(Environment, Social, and Governance). We plan to share our yearly achievements and activities transparently through our annual report, and enhance the effectiveness of our sustainability management by gathering our various stakeholders' opinions and reflecting them.
Samsung Bioepis selects suppliers according to strict criteria aimed at building and operating a responsible supply chain, and they are managed through a transparent registration system. For CMOs in particular, we carefully select companies that have obtained international standard (ISO) certification for their environmental management, energy management, and occupational health and safety management systems, verifying that they systematically practice environmental and safety management. Going a step further, we are reviewing the introduction of a policy for the preferential use of eco-friendly transportation as a way of governing the environmental impact of our supply chain. We are also discussing the use of additional ESG evaluation items in our processes for supplier selection, regular evaluations, and contract renewal.
Key Suppliers in the Samsung Bioepis Supply Chain
Our partners include raw material suppliers, contract research organizations, contract manufacturing organizations (CMOs), logistics companies (transport, storage), and commercialization partners. Partners from whom annual purchases exceed 1 billion KRW, including CMOs (DS/DP/FDP), logistics companies and raw material suppliers, are designated as key suppliers, and to these partners we apply active selection and management processes.
Supplier EvaluationsSupplier qualification process
When sourcing from CMOs for clinical or commercial purposes, we conduct supplier evaluations to minimize risk in these relationships while boosting the competitiveness of our partners. Led by the Quality Team, supplier qualification covers not only quality management systems, but also facilities, equipment, manufacturing management systems and more. We meet regularly with key partners such as CMOs and logistics companies to share the results of these evaluations and discuss steps for improvement. Going forward, we plan to add ESG evaluation items to the processes for supplier selection, and contract renewal.
By increasing market competition, biosimilars have become an important lever for the innovation of next generation biologics. While our focus remains on the development of high-quality biosimilars, we are now taking our first steps into novel biologic development. We are also looking to enhance the patient experience, including the development of ergonomic autoinjector devices and extended storage conditions for our products.
At Samsung Bioepis, we have established environmental management principles and systems adhered to the green management philosophy, which we are practicing across the company. As an R&D company with low energy consumption, we are not subject to targets for Greenhouse Gas (GHG) emissions and energy consumption. Nonetheless, we are continuing our proactive efforts to save energy and reduce emissions. Furthermore, we have put in place a management system for water resources, waste, air pollutants and hazardous chemicals, and we are introducing eco-friendly packaging materials as part of building a circular economy and enhancing resource efficiency.